Pioneering a New Era of Gene Therapy. We are developing Anellovectors™, the first potentially redosable and targetable gene therapy platform, by harnessing the human commensal virome.
Employees: 11-50
Total raised: $203.5M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Altitude L... | altitudels... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.03.2023 | Series C | $86.5M | - |
| 28.07.2021 | Series B | $117M | - |
Mentions in press and media 10
| Date | Title | Description |
| 12.03.2025 | The Dawn of Autonomous Science: Lila Sciences and the Future of Discovery | In the world of scientific research, a new player has emerged, promising to change the game. Lila Sciences, a startup born from the innovative incubator Flagship Pioneering, has raised a staggering $200 million in seed funding. This infusio... |
| 10.03.2025 | Lila Sciences raises $200M to accelerate autonomous scientific research Your vote of support is important to us and it helps us keep the content FREE. One click below supports our mission to provide f... | Artificial intelligence-powered scientific discovery startup Lila Sciences is the latest company to emerge from Flagship Pioneering Inc.’s biotechnology incubator, and it’s backed by a staggering $200 million in seed funding. The startup, w... |
| 09.03.2023 | Ring Therapeutics Secures $86.5M in Series C Funding | Ring Therapeutics, a Cambridge, MA-based life sciences company focused on advancing a gene therapy, raised $86.5M in Series C funding. The round, which brought total funds raised to date to $230M, was led by Alexandria Venture Investments, ... |
| 09.03.2023 | Ring Therapeutics Scores $86.5M Series C | CAMBRIDGE, MA, Ring Therapeutics today announced that it raised $86.5 million in Series C funding. >> Click here for more funding data on Ring Therapeutics >> To export Ring Therapeutics funding data to PDF and Excel, click ... |
| 09.03.2023 | Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines | - |
| 28.07.2021 | TPG and Brookfield add billions to the climate-tech coffers | As interest in climate-tech grows, so are the mega war chests. Paid Content Building a world economy in WordPress From WP Engine Growth equity and buyout investor TPG announced earlier this week that it had raised $5.4 billion to invest in ... |
| 28.07.2021 | TPG and Brookfield add billions to the climate-tech coffers | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. As interest in climate-tech grows, so are the mega war chests. Growth equity and buyout investor ... |
| 28.07.2021 | Ring Therapeutics Raises $117M in Series B Funding | Ring Therapeutics, a Cambridge, Mass.-based life sciences company, raised $117m in Series B funding. Backers included Invus, Altitude Life Science Ventures, Partners Investment, UPMC Enterprises, funds and accounts advised by T. Rowe Price ... |
| 28.07.2021 | Ring Therapeutics calls in a whopping $117M series B for gene therapies | Gene therapies come with a roster of limitations from tissue-specific tropism to tolerability issues to lack of potency to the inability to re-dose. Ring Therapeutics is looking to tackle these challenges head-on and now has $117 million to... |
| - | Ring Therapeutics | “Ring Therapeutics is creating anellovirus vectors that can safely and effectively deliver therapies for diverse modalities to target cells and tissues.” |